BioMed Alliance Board of Director Ulrich Jaeger argues that EU funding is crucial in allowing medical researchers across member states to collaborate in the development of new treatments. In Framework Programme 9, processes must be optimised and the budget boosted - to deliver for patients and the economy.  Read the article here

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.